Target Name: CDC73
NCBI ID: G79577
Review Report on CDC73 Target / Biomarker Content of Review Report on CDC73 Target / Biomarker
CDC73
Other Name(s): HPT-JT | cell division cycle 73 Paf1/RNA polymerase II complex component-like protein | Parafibromin | HRPT2 | cell division cycle 73, Paf1/RNA polymerase II complex component, homolog | Cell division cycle 73 | Cell division cycle protein 73 homolog | Hyperparathyroidism 2 (with jaw tumor) | HYX | FIHP | CDC73_HUMAN | Hyperparathyroidism 2 protein | Familial isolated hyperparathyroidism | hyperparathyroidism 2 protein | cell division cycle 73 | FLJ23316 | hyperparathyroidism 1 | Paf1/RNA polymerase II complex component | HPTJT | HRPT1 | cell division cycle protein 73 homolog | C1orf28

The Potential Drug Target (Biomarker) CD73: Unlocking the Secret to Effective Therapies

Introduction

CD73, a protein expressed in various tissues of the human body, has been identified as a potential drug target and biomarker. Its unique structure and function make it an attractive target for drug development due to its involvement in various cellular processes, including cell signaling, inflammation, and stress responses. In this article, we will explore the biology of CD73, its potential drug targets, and its role as a biomarker in disease diagnosis and treatment.

The biology of CD73

CD73 is a member of the superfamily of cytoskeletal proteins, known as the actinin family 73. It is a 21-kDa protein that was first identified in the 1970s by researchers who showed that it was involved in the regulation of cell proliferation and differentiation. Since Then, numerous studies have confirmed its role in various cellular processes, including cell signaling, cytoskeletal organization, and stress responses.

CD73 is a key component of the cytoskeleton, which is a complex network of filaments and microtubules that provides structural support to cells and helps maintain their shape. It plays a crucial role in the regulation of cell division by controlling the movement of organelles , such as the mitochondria and endoplasmic reticulum, to the plasma membrane.

In addition to its role in cytoskeletal organization, CD73 is also involved in the regulation of cell signaling pathways. It has been shown to be involved in the development and maintenance of various signaling pathways, including the TGF-灏? pathway, which plays a crucial role in cell growth, differentiation, and stress responses.

CD73's potential drug targets

CD73's involvement in various cellular processes makes it an attractive target for drug development. Several studies have identified potential drug targets for CD73, including:

1. Cell signaling: CD73 has been shown to be involved in the regulation of various signaling pathways, including TGF-灏?, which is involved in cell growth, differentiation, and stress responses. Therefore, potential drugs that target CD73 may have therapeutic benefits for various diseases, such as cancer, neurodegenerative diseases, and autoimmune disorders.
2. Cell division: CD73 is involved in the regulation of cell division, which makes it an attractive target for drugs that aim to induce cell death or prevent cell proliferation. This may be useful for the treatment of various cancers, including breast, ovarian, and prostate cancers.
3. Inflammation: CD73 has been shown to be involved in the regulation of inflammation, which may make it an attractive target for drugs that aim to alleviate inflammation and reduce the risk of chronic diseases.

CD73 as a biomarker

CD73 has also been identified as a potential biomarker for various diseases. Its involvement in various cellular processes makes it an attractive target for biomarkers that aim to diagnose or predict the progression of diseases. Some studies have shown that CD73 levels can be used as a diagnostic marker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

In addition to its potential as a diagnostic marker, CD73 has also been shown to be involved in the regulation of various biological processes, including cell signaling, stress responses, and inflammation. Therefore, its levels may also be useful for the prediction of disease outcomes , such as the response to therapeutic treatments.

Conclusion

In conclusion, CD73 is a protein that has been identified as a potential drug target and biomarker. Its unique structure and function make it an attractive target for drug development due to its involvement in various cellular processes. Further research is needed to fully understand its role in the regulation of cell signaling, cell division, inflammation, and stress responses, as well as its potential as a diagnostic and predictive marker for various diseases.

Protein Name: Cell Division Cycle 73

Functions: Tumor suppressor probably involved in transcriptional and post-transcriptional control pathways. May be involved in cell cycle progression through the regulation of cyclin D1/PRAD1 expression. Component of the PAF1 complex (PAF1C) which has multiple functions during transcription by RNA polymerase II and is implicated in regulation of development and maintenance of embryonic stem cell pluripotency. PAF1C associates with RNA polymerase II through interaction with POLR2A CTD non-phosphorylated and 'Ser-2'- and 'Ser-5'-phosphorylated forms and is involved in transcriptional elongation, acting both independently and synergistically with TCEA1 and in cooperation with the DSIF complex and HTATSF1. PAF1C is required for transcription of Hox and Wnt target genes. PAF1C is involved in hematopoiesis and stimulates transcriptional activity of KMT2A/MLL1; it promotes leukemogenesis through association with KMT2A/MLL1-rearranged oncoproteins, such as KMT2A/MLL1-MLLT3/AF9 and KMT2A/MLL1-MLLT1/ENL. PAF1C is involved in histone modifications such as ubiquitination of histone H2B and methylation on histone H3 'Lys-4' (H3K4me3). PAF1C recruits the RNF20/40 E3 ubiquitin-protein ligase complex and the E2 enzyme UBE2A or UBE2B to chromatin which mediate monoubiquitination of 'Lys-120' of histone H2B (H2BK120ub1); UB2A/B-mediated H2B ubiquitination is proposed to be coupled to transcription. PAF1C is involved in mRNA 3' end formation probably through association with cleavage and poly(A) factors. In case of infection by influenza A strain H3N2, PAF1C associates with viral NS1 protein, thereby regulating gene transcription. Connects PAF1C with the cleavage and polyadenylation specificity factor (CPSF) complex and the cleavage stimulation factor (CSTF) complex, and with Wnt signaling. Involved in polyadenylation of mRNA precursors

The "CDC73 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDC73 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CDCA2 | CDCA3 | CDCA4 | CDCA4P3 | CDCA5 | CDCA7 | CDCA7L | CDCA8 | CDCP1 | CDCP2 | CDH1 | CDH10 | CDH11 | CDH12 | CDH13 | CDH13-AS2 | CDH15 | CDH16 | CDH17 | CDH18 | CDH19 | CDH2 | CDH20 | CDH22 | CDH23 | CDH24 | CDH26 | CDH3 | CDH4 | CDH5 | CDH6 | CDH7 | CDH8 | CDH9 | CDHR1 | CDHR18P | CDHR2 | CDHR3 | CDHR4 | CDHR5 | CDIN1 | CDIP1 | CDIPT | CDIPTOSP | CDK1 | CDK10 | CDK11A | CDK11B | CDK12 | CDK13 | CDK14 | CDK15 | CDK16 | CDK17 | CDK18 | CDK19 | CDK2 | CDK20 | CDK2AP1 | CDK2AP2 | CDK2AP2P2 | CDK2AP2P3 | CDK3 | CDK4 | CDK5 | CDK5R1 | CDK5R2 | CDK5RAP1 | CDK5RAP2 | CDK5RAP3 | CDK6 | CDK6-AS1 | CDK7 | CDK8 | CDK9 | CDKAL1 | CDKL1 | CDKL2 | CDKL3 | CDKL4 | CDKL5 | CDKN1A | CDKN1B | CDKN1C | CDKN2A | CDKN2A-DT | CDKN2AIP | CDKN2AIPNL | CDKN2AIPNLP1 | CDKN2B | CDKN2B-AS1 | CDKN2C | CDKN2D | CDKN3 | CDNF | CDO1 | CDON | CDPF1 | CDR1 | CDR2